Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2006-08-18

Clinical Trial Update: Omega-3 Fatty Acids in Bipolar Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial of omega-3 fatty acids for bipolar disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: National Center for Complementary and Integrative Health (NCCIH) | Conditions: Bipolar Disorder | Phase 2 | Status: COMPLETED